Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Microbicides Acceptability Among Sexually Active Young Women

27 februari 2017 uppdaterad av: University of North Carolina, Chapel Hill

Microbicide-Use Adherence, Acceptability, and Attitudes Among Sexually Active Young Women Participating in a Phase I Microbicide Trial (MTN 004) "Tell Juliana"

ATN 062 is designed to gain scientific knowledge of microbicide-use adherence, acceptability, and attitudes among sexually active young women

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

ATN 062 will take place in parallel to another study, MTN 004, "Phase I Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel™) Applied Vaginally in Sexually Active Young Women." ATN 062 will use quantitative and qualitative research methods. The quantitative method will consist of a computerized diary used by participants during the 14 days of the gel trial of MTN 004. The qualitative methods will include email messages sent by participants to a research assistant as a supplement to the diaries, as well as in-depth interviews through teleconferences to contextualize the recorded events. All study activities will be timed to coincide with those of MTN 004

Studietyp

Observationell

Inskrivning (Faktisk)

59

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Florida
      • Tampa, Florida, Förenta staterna, 33606
        • University of South Florida College of Medicine
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • University of Pittsburgh Medical Center
      • San Juan, Puerto Rico, 00936
        • University Pediatric Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 24 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

HIV-negative women ages 18 to 24 years old who are non-pregnant, sexually active and enrolled in MTN 004 will be offered the option to enroll in ATN 062. Approximately half of the participants will be recruited in San Juan, PR, and the other half in Tampa, FL.

Beskrivning

Inclusion Criteria:

  • Currently enrolled in MTN 004.
  • Willing and able to provide written informed consent for ATN 062.
  • Willing to participate as required by protocol, including completion of all assessments and follow-ups.

Exclusion Criteria:

  • Refuses to have teleconferences audio recorded.
  • Any social or medical condition that, in the investigator's opinion, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Kohort
  • Tidsperspektiv: Blivande

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
1
Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study. They will also have the opportunity to send emails to "Juliana" during the course of the study.
Andra namn:
  • HEC Placebo Gel
  • HEC Gel
2
Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study. They will also have the opportunity to send emails to "Juliana" during the course of the study.
Andra namn:
  • HEC Placebo Gel
  • HEC Gel
3
Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study. They will also have the opportunity to send emails to "Juliana" during the course of the study.
Andra namn:
  • HEC Placebo Gel
  • HEC Gel

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Microbicide use adherence as measured by a computerized phone diary
Tidsram: 21 days(through end of study)
21 days(through end of study)
Microbicide use adherence as measured by e-mail messages
Tidsram: 21 days (through end of study)
21 days (through end of study)
Microbicide use adherence as measured by in-depth interviews via teleconference
Tidsram: 21 days (through end of study)
21 days (through end of study)
Microbicide use acceptability as measured by a computerized phone diary
Tidsram: 21 days (through end of study)
21 days (through end of study)
Microbicide use acceptability as measured by e-mail messages
Tidsram: 21 days (through end of study)
21 days (through end of study)
Microbicide use acceptability as measured by in-depth interviews via teleconferences
Tidsram: 21 days (through end of study)
21 days (through end of study)
Microbicide use attitudes as measured by a computerized phone diary
Tidsram: 21 days (through end of study)
21 days (through end of study)
Microbicide use attitudes as measured by e-mail messages
Tidsram: 21 days (through end of study)
21 days (through end of study)
Microbicide use attitudes as measured by in-depth interviews via teleconferences
Tidsram: 21 days (through end of study)
21 days (through end of study)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Alex Carballo-Diéguez, PhD, HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 augusti 2007

Primärt slutförande (Faktisk)

1 november 2009

Avslutad studie (Faktisk)

1 november 2009

Studieregistreringsdatum

Först inskickad

21 juni 2007

Först inskickad som uppfyllde QC-kriterierna

21 juni 2007

Första postat (Uppskatta)

22 juni 2007

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 februari 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

27 februari 2017

Senast verifierad

1 maj 2016

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på HIV-infektioner

Kliniska prövningar på Automated diary system

3
Prenumerera